Literature DB >> 28503880

Individualised medicine: why we need Bayesian dosing.

Joni Donagher1, Jennifer H Martin2, Michael A Barras3,4.   

Abstract

Individualised drug dosing has been shown to improve patient outcomes and reduce adverse drug events. One method of individualised medicine is the Bayesian approach, which uses prior information about how the population responds to therapy, to inform clinicians about how a specific individual is responding to their current therapy. This information is then used to make changes to the dose. Studies using a Bayesian approach to adjust drug dosing have shown that clinicians are able to achieve a therapeutic range quicker than standard practice. If concentration is related to a pharmacodynamic end-point, this means that the drug will be more effective, and the side-effects will be minimised. Unfortunately, the software options to assist with Bayesian dosing in Australia are limited. The aims of this article are to demystify the concepts of Bayesian dosing, set the context of the Bayesian approach using reference to other dosing strategies and discuss its benefits over current dosing methods for a number of drugs. The article is targeted to medical and pharmacy clinicians, and there is a practical clinical case to demonstrate how this method could be used in everyday clinical practice.
© 2017 Royal Australasian College of Physicians.

Entities:  

Keywords:  Bayesian; individualised drug dosing

Mesh:

Substances:

Year:  2017        PMID: 28503880     DOI: 10.1111/imj.13412

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  12 in total

1.  Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin.

Authors:  Stijn W van Beek; Rob Ter Heine; Ron J Keizer; Cecile Magis-Escurra; Rob E Aarnoutse; Elin M Svensson
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

2.  Can Population Pharmacokinetics of Antibiotics be Extrapolated? Implications of External Evaluations.

Authors:  Yu Cheng; Chen-Yu Wang; Zi-Ran Li; Yan Pan; Mao-Bai Liu; Zheng Jiao
Journal:  Clin Pharmacokinet       Date:  2021-01       Impact factor: 6.447

3.  An evaluation of the user-friendliness of Bayesian forecasting programs in a clinical setting.

Authors:  Alzana A Kumar; Marc Burgard; Sonya Stacey; Indy Sandaradura; Tony Lai; Christine Coorey; Marisol Cincunegui; Christine E Staatz; Stefanie Hennig
Journal:  Br J Clin Pharmacol       Date:  2019-08-06       Impact factor: 4.335

4.  Feasibility of Extrapolating Randomly Taken Plasma Samples to Trough Levels for Therapeutic Drug Monitoring Purposes of Small Molecule Kinase Inhibitors.

Authors:  Ruben A G van Eerden; Esther Oomen-de Hoop; Aad Noordam; Ron H J Mathijssen; Stijn L W Koolen
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-04

Review 5.  Therapeutic drug monitoring of oral targeted antineoplastic drugs.

Authors:  Anna Mueller-Schoell; Stefanie L Groenland; Oliver Scherf-Clavel; Madelé van Dyk; Wilhelm Huisinga; Robin Michelet; Ulrich Jaehde; Neeltje Steeghs; Alwin D R Huitema; Charlotte Kloft
Journal:  Eur J Clin Pharmacol       Date:  2020-11-09       Impact factor: 2.953

Review 6.  Bayesian estimation of pharmacokinetic parameters: an important component to include in the teaching of clinical pharmacokinetics and therapeutic drug monitoring.

Authors:  Dion R Brocks; Dalia A Hamdy
Journal:  Res Pharm Sci       Date:  2020-11-27

Review 7.  A Call to Action Toward Optimizing the Electrical Dose Received by Neural Targets in Spinal Cord Stimulation Therapy for Neuropathic Pain.

Authors:  Krishnan Chakravarthy; Rajiv Reddy; Adnan Al-Kaisy; Thomas Yearwood; Jay Grider
Journal:  J Pain Res       Date:  2021-09-07       Impact factor: 2.832

8.  Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients.

Authors:  Patrick O Hanafin; Roger L Nation; Marc H Scheetz; Alexandre P Zavascki; Ana M Sandri; Andrea L Kwa; Benjamin P Z Cherng; Christine J Kubin; Michael T Yin; Jiping Wang; Jian Li; Keith S Kaye; Gauri G Rao
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-11-23

9.  Chinese ICU physicians' knowledge of antibiotic pharmacokinetics/pharmacodynamics (PK/PD): a cross-sectional survey.

Authors:  Wenchao Mao; Difan Lu; Jia Zhou; Junhai Zhen; Jing Yan; Li Li
Journal:  BMC Med Educ       Date:  2022-03-14       Impact factor: 2.463

10.  A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis.

Authors:  Stijn W van Beek; Rob Ter Heine; Jan-Willem C Alffenaar; Cecile Magis-Escurra; Rob E Aarnoutse; Elin M Svensson
Journal:  Clin Pharmacokinet       Date:  2021-02-22       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.